Wire · operational-macro
Curium strikes up to $8B deal for radiopharma rival Lantheus
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
Curium has agreed to acquire radiopharmaceutical company Lantheus in a deal worth up to $8 billion, combining global manufacturing and diagnostic imaging capabilities. The merger, expected to complete in early 2027, will create a private firm with a broad presence in oncology, neurology, and cardiology across 70+ countries.
This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Radiopharma founders should expect a shift towards bolder consolidation and an expanded private-player model reshaping product supply and innovation paths in nuclear medicine. Your potential partnerships and competitive dynamics have just tightened around a bigger entity controlling critical US and global radiopharma assets.
◆ Coverage
2 sources · 4 Aug 2026
◆ Related on Wire
◆ Topics